BCL2 and neoplasm: The cell response to these agents is typically cytostatic allowing tumour cells to quickly adapt and acquire resistance; however, ERK1/2 inhibition increases the expression of multiple proapoptotic BOPs, thereby sensitising them to BH3‐mimetics targeting BCL‐XL and/or BCL2 or MCL1.